title: Steroid avoidance in renal transplant patients maintained on a cyclosporine-based protocol.
abstract: OBJECTIVE
  The aim of this study was to analyze the effect of steroid avoidance, as compared with our pre-existing protocol that contained steroids, on renal allograft and patient survival. Secondary outcomes included body weight, diabetes, hyperlipidemia, and infection.
  
  
  METHODS
  This retrospective chart review of the results of steroid avoidance was performed in 169 patients who had undergone renal transplant between January 2000 and March 2002 and had received an immunosuppression regimen of cyclosporine, mycophenolate mofetil, and prednisone; and 148 patients who had undergone transplant between November 2002 and November 2004 who had received induction immunosuppression with a steroid taper by postoperative day 4 and were maintained on cyclosporine and mycophenolate mofetil.
  
  
  RESULTS
  One-year allograft survival rates, rejection-free graft survival rates, and patient survival rates were 88%, 76%, and 97%, respectively, in the steroid-maintenance group compared with 90%, 74%, and 96%, respectively, in the steroid-avoidance group (P = NS). No differences were detected in multiple secondary variables related to the metabolic effects of steroid therapy.
  
  
  CONCLUSIONS
  These data suggest that steroid avoidance can be performed safely and effectively in patients on a cyclosporine-based protocol of immunosuppression. Longer follow-ups are suggested to determine the effects of limited steroid exposure on the metabolic profiles of patients.
authors.affiliation: Department of Medicine, Allegheny General Hospital, Pittsburgh, PA, USA.
authors.forename: Tina Y
authors.initials: TY
authors.lastname: Ko
authors.forename: Julie A
authors.initials: JA
authors.lastname: Haddy
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Marcus
authors.forename: Barbara J
authors.initials: BJ
authors.lastname: Carpenter
authors.forename: Dai D
authors.initials: DD
authors.lastname: Nghiem
authors.forename: Rita L
authors.initials: RL
authors.lastname: McGill
authors.forename: Stephen E
authors.initials: SE
authors.lastname: Sandroni
authors.forename: Satish
authors.initials: S
authors.lastname: Patel
authors.forename: Molly
authors.initials: M
authors.lastname: Breckenridge
authors.forename: Kalathil K
authors.initials: KK
authors.lastname: Sureshkumar
mesh_terms: D000368:Aged; D016572:Cyclosporine / Q000008:administration & dosage*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation / Q000276:immunology / Q000379:methods*; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011239:Prednisolone / Q000008:administration & dosage*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D009173:Mycophenolic Acid